PDCD1 and head and neck squamous cell carcinoma: The immune system is known to be significantly involved in HNSCC progression [5,6,7], and anti-programmed cell death protein 1 (PD-1) immune checkpoint inhibitors have been approved to treat recurrent and/or metastatic HNSCCs that are refractory to platinum therapy [8,9].